{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:08:45Z","timestamp":1791497325775,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA0918500"],"award-info":[{"award-number":["2024YFA0918500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202473014"],"award-info":[{"award-number":["3502Z202473014"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijbiomac.2025.149942","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:02:11Z","timestamp":1766793731000},"page":"149942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Development and characterization of CR101-ADC, a fully-human anti-claudin18.2 monoclonal antibody-drug conjugate"],"prefix":"10.1016","volume":"339","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ario","family":"de Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149942_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Center"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149942_bb0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ajco.13654","article-title":"Overview of epidemiological characteristics, clinical features, and risk factors of gastric cancer in Asia-Pacific Region","volume":"18","author":"Akbari","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00404","article-title":"Emerging therapies in the management of advanced-stage gastric cancer","volume":"9","author":"Kumar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0030","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.2147\/JIR.S499403","article-title":"The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy","volume":"18","author":"Zhang","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"31","key":"10.1016\/j.ijbiomac.2025.149942_bb0035","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase iii granite-1 study","volume":"31","author":"Ohtsu","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149942_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2018.09.008","article-title":"The claudins: from tight junctions to biological systems","volume":"44","author":"Tsukita","year":"2019","journal-title":"Trends Biochem.Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149942_bb0050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/j.gastro.2011.10.040","article-title":"Deficiency of claudin-18 causes paracellular h+ leakage, up-regulation of interleukin-1\u03b2, and atrophic gastritis in mice","volume":"142","author":"Hayashi","year":"2012","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.ijbiomac.2025.149942_bb0055","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149942_bb0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-specific chimeric antigen receptor engineered t cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149942_bb0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"Her2-targeted therapies beyond breast cancer - an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/19420862.2014.985489","article-title":"Generation of potent mouse monoclonal antibodies to self-proteins using t-cell epitope \u201ctags\u201d","volume":"7","author":"Percival-Alwyn","year":"2015","journal-title":"Mabs"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149942_bb0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/0008-5472.CAN-10-2292","article-title":"Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric hbcag virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases","volume":"71","author":"Klamp","year":"2011","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149942_bb0080","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/ijc.28857","article-title":"Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer","volume":"135","author":"Micke","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149942_bb0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for imab362 antibody in pancreatic neoplasms","volume":"134","author":"W\u00f6ll","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149942_bb0090","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1369\/0022155411420569","article-title":"Claudin-18 is an early-stage marker of pancreatic carcinogenesis","volume":"59","author":"Tanaka","year":"2011","journal-title":"J. Histochem. Cytochem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark. Res."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.149942_bb0100","article-title":"Safety and preliminary efficacy results of ibi389, an anti-cldn18.2\/cd3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","volume":"42","author":"Zheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0105","series-title":"Preclinical Evaluation of hbm7022, an hbicetm 2+1 cldn18.2 x cd3 Bispecific Antibody, for Gastric Cancer","author":"Ming-Jin Jheng","year":"2021"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149942_bb0110","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2023.06.037","article-title":"Cldn18.2 bite engages effector and regulatory t cells for antitumor immune response in preclinical models of pancreatic cancer","volume":"165","author":"Xu","year":"2023","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.149942_bb0115","article-title":"Safety results of q-1802, a claudin18.2\/pd-l1 bsabs, in patients with relapsed or refractory solid tumors in a phase 1 study","volume":"40","author":"Gong","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149942_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006704","article-title":"Cldn18.2 and 4-1bb bispecific antibody givastomig exerts antitumor activity through cldn18.2-expressing tumor-directed t-cell activation","volume":"11","author":"Gao","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149942_bb0125","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0130","article-title":"Targeting cldn18.2 in cancers of the gastrointestinal tract: new drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149942_bb0135","article-title":"Cmg901, a claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149942_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","article-title":"Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals","volume":"481","author":"T\u00fcreci","year":"2011","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149942_bb0145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/acs.bioconjchem.5c00037","article-title":"Fc multisite conjugation and prolonged delivery of the folate-targeted drug conjugate ec140","volume":"36","author":"Zheng","year":"2025","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0150","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"Tuereci","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149942_bb0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"issue":"D1","key":"10.1016\/j.ijbiomac.2025.149942_bb0160","doi-asserted-by":"crossref","first-page":"D933","DOI":"10.1093\/nar\/gkac958","article-title":"Ensembl 2023","volume":"51","author":"Martin","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149942_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for rna-seq data with deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149942_bb0170","article-title":"Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation-Amsterdam"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13578-024-01213-9","article-title":"Deubiquitinase psmd7 facilitates pancreatic cancer progression through activating nocth1 pathway via modifying sox2 degradation","volume":"14","author":"Luo","year":"2024","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149942_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108064","article-title":"The transcription factor creb regulates epithelial-mesenchymal transition of lens epithelial cells by phosphorylation-dependent and phosphorylation-independent mechanisms","volume":"301","author":"Zhang","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149942_bb0185","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/PAS.0b013e318163a8f8","article-title":"Immunohistochemical staining of reg iv and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma","volume":"32","author":"K","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000529681","volume":"46","author":"Lordick","year":"2023","journal-title":"Oncol. Res. Treat."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149942_bb0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.149942_bb0200","article-title":"A phase 1\/2 study of LM-302, an anti-claudin 18.2 (CLDN18. 2) antibody-drug conjugate in patients with advanced gastric\/gastroesophageal junction cancer","volume":"42","author":"Bai","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.149942_bb0205","article-title":"Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18. 2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L) 1 antibody (ZSAB-Calm)","volume":"42","author":"Fan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0210","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.annonc.2024.05.311","article-title":"Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) ibi343 in patients (pts) with solid tumors and gastric\/gastro-esophageal junction adenocarcinoma (G\/GEJ AC): a phase study","volume":"35","author":"Liu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.149942_bb0215","article-title":"Safety and efficacy of ibi343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: preliminary results from a phase 1 study","volume":"42","author":"Yu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149942_bb0220","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.annonc.2024.08.676","article-title":"CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric\/gastroesophageal junction cancer (GC\/GEJC): a phase i study","volume":"35","author":"Xu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.ijbiomac.2025.149942_bb0225","doi-asserted-by":"crossref","first-page":"11026","DOI":"10.1039\/C9RA00834A","article-title":"Spermine modified polymeric micelles with ph-sensitive drug release for targeted and enhanced antitumor therapy","volume":"9","author":"Chen","year":"2019","journal-title":"RSC Adv."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025104996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025104996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:28:30Z","timestamp":1769506110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025104996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"alternative-id":["S0141813025104996"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149942","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of CR101-ADC, a fully-human anti-claudin18.2 monoclonal antibody-drug conjugate","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149942"}}